NEW YORK, Oct. 7 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) today began trading the stock of Manhattan Pharmaceutical Inc, under the ticker symbol MHA. Manhattan Pharmaceuticals, Inc. is a development stage pharmaceutical company based in New York. It acquires and develops proprietary prescription drugs for large, underserved patient populations, and is developing Oleoyl estrone, an orally administered therapeutic for weight loss. "We gladly welcome Manhattan Pharmaceutical Inc. to the American Stock Exchange," Amex Equities Group Senior Vice President John McGonegal said. "We look forward to supporting the company's effort to reach a wider investor audience and hope they will avail themselves to the broad array of services we provide to our listed companies." "The Amex listing, which was one of our corporate milestones for 2005, should give us added visibility and improve the liquidity of our shares, attracting a broader investor base," said Douglas Abel, Manhattan Pharmaceutical's chief executive officer. Manhattan Pharmaceutical Inc. has selected HBH Specialists as the specialist in its stock. For more information on MHA, or any Amex-listed company, please visit http://www.amex.com/. The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 169 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit http://www.amex.com/. DATASOURCE: The American Stock Exchange CONTACT: Javier E. David of The American Stock Exchange, +1-212-306-1440, Web site: http://www.amex.com/

Copyright